Аннотация:
Objective: to investigate the efficacy and safety of Cavinton® Comforte (Vinpocetine) in patients with initial manifestations of chronic cere-brovascular disease (CVD) in outpatient neurological and therapeutic practice. Patients and methods. The program included 4410 patients with a verified diagnosis of Stage I-II dyscirculatory encephalopathy. All the patients took Cavinton® Comforte 10 mg thrice daily for 3 months. The patients underwent neurological and general physical examinations, laboratory tests, functional diagnostic (electrocardiography, Doppler ultrasound), and neuroimaging techniques (magnetic resonance imaging). Neuropsychological tests for attention, memory, visual-spatial and executive functions were used to assess cognitive impairment. Results. Therapy with this drug showed a high efficiency in terms of both subjective characteristics and the data of neuropsychological tests for attention, memory, visual-spatial and executive functions. At the same time, the improveme
Табеева Г. Р. Гюзяль Рафкатовна 1954-
Калимеева Е. Ю. Елена Юрьевна 1986-
Коберская Н. Н. Надежда Николаевна 1969-
Гереева С. И. Саидат Имамутдиновна 1992-
Tabeeva G. R. Gyuzyal` Rafkatovna 1954-
Kalimeeva E. Yu. Elena Yuryevna 1986-
Koberskaya N. N. Nadezhda Nikolaevna 1969-
Gereeva S. I. Saidat Imamutdinovna 1992-
Possibilities of therapy for early manifestations of chronic cerebral ischemia: Results of the PROFILE program
Текст визуальный непосредственный
Неврология, нейропсихиатрия, психосоматика
ИМА-Пресс
Т. 9, Вып. 3 С. 36-41
2017
Статья
Cerebrovascular disease Chronic cerebral ischemia Dyscirculatory encephalopathy
Objective: to investigate the efficacy and safety of Cavinton® Comforte (Vinpocetine) in patients with initial manifestations of chronic cere-brovascular disease (CVD) in outpatient neurological and therapeutic practice. Patients and methods. The program included 4410 patients with a verified diagnosis of Stage I-II dyscirculatory encephalopathy. All the patients took Cavinton® Comforte 10 mg thrice daily for 3 months. The patients underwent neurological and general physical examinations, laboratory tests, functional diagnostic (electrocardiography, Doppler ultrasound), and neuroimaging techniques (magnetic resonance imaging). Neuropsychological tests for attention, memory, visual-spatial and executive functions were used to assess cognitive impairment. Results. Therapy with this drug showed a high efficiency in terms of both subjective characteristics and the data of neuropsychological tests for attention, memory, visual-spatial and executive functions. At the same time, the improveme